A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke

Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs HT 3951 (Primary)
  • Indications Motor neuron disease
  • Focus Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Dart NeuroScience
  • Most Recent Events

    • 16 Feb 2017 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.
    • 16 Feb 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
    • 05 Feb 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top